Literature DB >> 21544396

Correlation between overexpression of c-met gene and the progression of gastric cancer.

Y Yonemura, M Kaji, Y Hirono, S Fushida, K Tsugawa, T Fujimura, I Miyazaki, S Harada, H Yamamoto.   

Abstract

The c-met oncogene encodes a receptor of hepatocyte growth factor (HGF), which has both mitogenic and motogenic activities. We have studied the c-met gene expression in gastric cancer by immunohistochemical method using an antibody specific to the c-met beta-chain. c-met immunoreactivity was preferentially localize on the cell membrane, and 55 (43%) of 127 primary gastric cancers showed c-met immunoreactivity. Strong correlation was found between c-met expression in large tumors, lymph node involvement, serosal invasion, as well as peritoneal dissemination. Furthermore, c-met positive tumors had a tendency to metastasize to more distant lymph node sites. Regarding the macroscopic type, Borrmann type 4 gastric cancer showed the highest incidence (12/16, 76%) of positive c-met expression. Patients with c-met positive tumor ran a significantly poorer prognosis than those with c-met negative one. These results indicate that the c-met protein participates in the progression and invasion of stomach cancer, and that c-met tissue status is a useful biological marker in gastric cancer.

Entities:  

Year:  1996        PMID: 21544396

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.

Authors:  Nozomu Fuse; Yasutoshi Kuboki; Takeshi Kuwata; Tomohiro Nishina; Shigenori Kadowaki; Eiji Shinozaki; Nozomu Machida; Satoshi Yuki; Akira Ooki; Shinya Kajiura; Tetsuo Kimura; Takeharu Yamanaka; Kohei Shitara; Akiko Kawano Nagatsuma; Takayuki Yoshino; Atsushi Ochiai; Atsushi Ohtsu
Journal:  Gastric Cancer       Date:  2015-02-15       Impact factor: 7.370

2.  Value of c-Met for Predicting Progression of Precancerous Gastric Lesions in Rural Chinese Population.

Authors:  Yu Sun; Meng-Meng Tian; Li-Xin Zhou; Wei-Cheng You; Ji-You Li
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

3.  The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays.

Authors:  Kambiz Sotoudeh; Forough Hashemi; Zahra Madjd; Alireza Sadeghipour; Saadat Molanaei; Elham Kalantary
Journal:  Diagn Pathol       Date:  2012-05-28       Impact factor: 2.644

4.  Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma.

Authors:  Hai Cheng; Zhiling Yan; Xue Wang; Jiang Cao; Wei Chen; Kunming Qi; Dian Zhou; Jieyun Xia; Na Qi; Zhenyu Li; Kailin Xu
Journal:  Mol Cell Biochem       Date:  2019-07-23       Impact factor: 3.842

5.  A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.

Authors:  M Yashiro; T Nishii; T Hasegawa; T Matsuzaki; T Morisaki; T Fukuoka; K Hirakawa
Journal:  Br J Cancer       Date:  2013-10-15       Impact factor: 7.640

Review 6.  Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis.

Authors:  Zhi Peng; Yan Zhu; Qianqian Wang; Jing Gao; Yilin Li; Yanyan Li; Sai Ge; Lin Shen
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

7.  Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer.

Authors:  Qiumo Zhang; Haiyang Zhang; Tao Ning; Dongying Liu; Ting Deng; Rui Liu; Ming Bai; Kegan Zhu; Jialu Li; Qian Fan; Guoguang Ying; Yi Ba
Journal:  Int J Nanomedicine       Date:  2020-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.